3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Hepatocellular
2
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Rectal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Lung Diseases
1
Esophageal Squamous Cell Carcinoma
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Solid Tumor
1
Adenocarcinoma of Lung
1
Adenocarcinoma
1
Interventions
Gemcitabine
15
pembrolizumab
13
Doxorubicin
13
Radiotherapy
12
Docetaxel
9
Nivolumab
8
Filgrastim
7
Cyclophosphamide
7
pazopanib
6
Ifosfamide
6
130-nm albumin-bound paclitaxel
5
Temozolomide
4
Irinotecan
4
Ipilimumab
4
Imatinib Mesylate
4
Albumin-Bound Paclitaxel
4
talimogene laherparepvec
3
surufatinib
3
pegfilgrastim
3
eribulin
3
atezolizumab
3
Vinorelbine
3
Sirolimus
3
Peripheral Blood Stem Cell Transplantation
3
PM 01183
3
Drug Therapy
3
Cisplatin
3
toripalimab
2
spartalizumab
2
selinexor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Sarcoma
×
Immunotherapy
×
Clear all
NCT03116529
2024-11-04
NEXIS
University of Maryland, Baltimore
Phase 1/2
Terminated
22 enrolled